BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Saw PE, Chen J, Song E. Targeting CAFs to overcome anticancer therapeutic resistance. Trends Cancer 2022:S2405-8033(22)00055-3. [PMID: 35331673 DOI: 10.1016/j.trecan.2022.03.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Li X, Yang J. Perspective Chapter: Critical Role of Hedgehog in Tumor Microenvironment. Tumor Microenvironment - New Insights [Working Title] 2023. [DOI: 10.5772/intechopen.108831] [Reference Citation Analysis]
2 Cheng B, Yu Q, Wang W. Intimate communications within the tumor microenvironment: stromal factors function as an orchestra. J Biomed Sci 2023;30:1. [PMID: 36600243 DOI: 10.1186/s12929-022-00894-z] [Reference Citation Analysis]
3 Shintani Y, Kimura T, Funaki S, Ose N, Kanou T, Fukui E. Therapeutic Targeting of Cancer-Associated Fibroblasts in the Non-Small Cell Lung Cancer Tumor Microenvironment. Cancers (Basel) 2023;15. [PMID: 36672284 DOI: 10.3390/cancers15020335] [Reference Citation Analysis]
4 Monteran L, Erez N. myCAFs are better than yours: targeting myofibroblasts potentiates immunotherapy. Trends Cancer 2023;9:1-2. [PMID: 36371342 DOI: 10.1016/j.trecan.2022.11.001] [Reference Citation Analysis]
5 Gu L, Liao P, Liu H. Cancer-associated fibroblasts in acute leukemia. Front Oncol 2022;12:1022979. [PMID: 36601484 DOI: 10.3389/fonc.2022.1022979] [Reference Citation Analysis]
6 Izci M, Maksoudian C, Gonçalves F, Aversa L, Salembier R, Sargsian A, Pérez Gilabert I, Chu T, Rios Luci C, Bolea-Fernandez E, Nittner D, Vanhaecke F, Manshian BB, Soenen SJ. Gold nanoparticle delivery to solid tumors: a multiparametric study on particle size and the tumor microenvironment. J Nanobiotechnology 2022;20:518. [PMID: 36494816 DOI: 10.1186/s12951-022-01727-9] [Reference Citation Analysis]
7 Luong T, Golivi Y, Nagaraju GP, El-Rayes BF. Fibroblast heterogeneity in pancreatic ductal adenocarcinoma: Perspectives in immunotherapy. Cytokine Growth Factor Rev 2022;68:107-15. [PMID: 36096869 DOI: 10.1016/j.cytogfr.2022.09.001] [Reference Citation Analysis]
8 Yuan B, Liu G, Dai Z, Wang L, Lin B, Zhang J. CYP1B1: A Novel Molecular Biomarker Predicts Molecular Subtype, Tumor Microenvironment, and Immune Response in 33 Cancers. Cancers (Basel) 2022;14. [PMID: 36428734 DOI: 10.3390/cancers14225641] [Reference Citation Analysis]
9 Wang Q, Zhang X, Du K, Wu X, Zhou Y, Chen D, Zeng L. Machine learning identifies characteristics molecules of cancer associated fibroblasts significantly correlated with the prognosis, immunotherapy response and immune microenvironment in lung adenocarcinoma. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1059253] [Reference Citation Analysis]
10 Wang W, Cheng B, Yu Q. Cancer-associated fibroblasts as accomplices to confer therapeutic resistance in cancer. Cancer Drug Resist 2022;5:889-901. [PMID: 36627901 DOI: 10.20517/cdr.2022.67] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhang X, Sun D, Zheng H, Rao Y, Deng Y, Liang X, chen J, Yang J. Comprehensive analysis of transcriptome characteristics and identification of TLK2 as a potential biomarker in dermatofibrosarcoma protuberans. Front Genet 2022;13:926282. [DOI: 10.3389/fgene.2022.926282] [Reference Citation Analysis]
12 Saltiki K, Simeakis G, Karapanou O, Alevizaki M. MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives. Eur J Endocrinol 2022;187:R53-63. [PMID: 35895692 DOI: 10.1530/EJE-22-0312] [Reference Citation Analysis]
13 Ritter A, Kreis NN, Hoock SC, Solbach C, Louwen F, Yuan J. Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells, Obesity and the Tumor Microenvironment of Breast Cancer. Cancers (Basel) 2022;14:3908. [PMID: 36010901 DOI: 10.3390/cancers14163908] [Reference Citation Analysis]
14 Yan H, Zhai B, Yang F, Chen Z, Zhou Q, Paiva-Santos AC, Yuan Z, Zhou Y. Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma. Front Pharmacol 2022;13:908713. [PMID: 35721107 DOI: 10.3389/fphar.2022.908713] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Lacina L, Szabo P, Klepáček I, Kolář M, Smetana K. Cancer-Associated Fibroblasts and Their Role in Cancer Progression. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_79] [Reference Citation Analysis]
16 Thiery J. Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions. Explor Target Antitumor Ther 2022;3:598-629. [PMID: 36338519 DOI: 10.37349/etat.2022.00103] [Reference Citation Analysis]